SCHEMBL17757153

SCHEMBL17757153

c1ccc(CNC2=Nc3ncncc3NC23CCCCC3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 10/20 0.37
▸ CYP3A4 P08684 10/20 0.37
▸ CYP2D6 P10635 9/20 0.37
▸ ALDH1A1 P00352 9/20 0.37
▸ HSD17B10 Q99714 7/20 0.37
▸ CYP2C19 P33261 6/20 0.37
▸ TSHR P16473 5/20 0.37
▸ CLK4 Q9HAZ1 4/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ ALOX15 P16050 6/20 0.36
▸ LMNA P02545 2/20 0.35
▸ EGFR P00533 1/20 0.34
▸ MAPK1 P28482 3/20 0.34
▸ USP2 O75604 2/20 0.34
▸ HPGD P15428 3/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17757936 0.84 CLK4 (0.39) CYP3A4CYP2D6ALDH1A1CYP2C19CLK4
SCHEMBL17757151 0.84 KMT2A (0.38) TSHRCLK4KMT2AEGFRKDM4E
SCHEMBL17757159 0.82 CYP1A2 (0.37) CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10
SCHEMBL17757162 0.81 EGFR (0.38) CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10
SCHEMBL17758129 0.79 SSTR3 (0.34) KMT2ASSTR3
SCHEMBL17757653 0.78 KMT2A (0.41) TSHRKMT2AMAPK1KDM4EMAPT
SCHEMBL14398518 0.78 KMT2A (0.41) TSHRKMT2AMAPK1KDM4EMAPT
SCHEMBL17757467 0.78 KMT2A (0.41) TSHRKMT2AMAPK1KDM4EMAPT
SCHEMBL17757157 0.78 EGFR (0.38) CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10
SCHEMBL17757155 0.78 KMT2A (0.37) TSHRKMT2AKDM4ESSTR3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
WO-2016075137-A1 SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 CYP1A2 3995/4885CYP3A4 4048/4885CYP2D6 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback